Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives Consensus Rating of "Buy" from Analysts

Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI - Get Free Report) have been assigned an average recommendation of "Buy" from the ten ratings firms that are currently covering the company, Marketbeat.com reports. Eight analysts have rated the stock with a buy recommendation and two have issued a strong buy recommendation on the company. The average 12 month price target among brokerages that have covered the stock in the last year is $9.13.

TRVI has been the topic of several analyst reports. HC Wainwright reaffirmed a "buy" rating on shares of Trevi Therapeutics in a research note on Wednesday. Needham & Company LLC restated a "buy" rating and issued a $8.00 price target on shares of Trevi Therapeutics in a research note on Wednesday. Leerink Partnrs upgraded Trevi Therapeutics to a "strong-buy" rating in a research report on Monday, September 9th. Raymond James began coverage on Trevi Therapeutics in a research report on Friday, August 30th. They issued an "outperform" rating and a $9.00 target price on the stock. Finally, EF Hutton Acquisition Co. I upgraded Trevi Therapeutics to a "strong-buy" rating in a research report on Monday, August 19th.

Institutional Investors Weigh In On Trevi Therapeutics

Several large investors have recently modified their holdings of the business. Logos Global Management LP boosted its holdings in shares of Trevi Therapeutics by 27.3% in the 2nd quarter. Logos Global Management LP now owns 2,800,000 shares of the company's stock valued at $8,344,000 after buying an additional 600,000 shares during the last quarter. Vanguard Group Inc. increased its holdings in Trevi Therapeutics by 2.7% in the 1st quarter. Vanguard Group Inc. now owns 2,303,648 shares of the company's stock valued at $7,948,000 after buying an additional 60,249 shares during the period. Bank of New York Mellon Corp raised its position in Trevi Therapeutics by 38.8% during the second quarter. Bank of New York Mellon Corp now owns 178,511 shares of the company's stock valued at $532,000 after purchasing an additional 49,884 shares in the last quarter. Price T Rowe Associates Inc. MD bought a new position in shares of Trevi Therapeutics in the first quarter worth about $47,000. Finally, Ally Bridge Group NY LLC acquired a new stake in Trevi Therapeutics in the second quarter valued at approximately $4,395,000. 95.76% of the stock is currently owned by institutional investors.

Trevi Therapeutics Price Performance

Shares of TRVI stock traded up $0.16 during trading hours on Friday, hitting $2.76. The company had a trading volume of 343,670 shares, compared to its average volume of 605,838. The stock has a market capitalization of $212.16 million, a PE ratio of -6.27 and a beta of 0.96. Trevi Therapeutics has a fifty-two week low of $1.07 and a fifty-two week high of $4.00. The company's fifty day moving average is $2.99 and its 200 day moving average is $2.91.

Trevi Therapeutics (NASDAQ:TRVI - Get Free Report) last issued its earnings results on Wednesday, November 6th. The company reported ($0.13) earnings per share for the quarter, missing analysts' consensus estimates of ($0.12) by ($0.01). During the same quarter in the previous year, the business posted ($0.08) earnings per share. Equities analysts forecast that Trevi Therapeutics will post -0.49 earnings per share for the current year.

About Trevi Therapeutics

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.